Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II clinical trial.
Authors: Xinfang Hou, Chen Wu, Shuai Li
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.4038
Source:
Full article
Abstract
4038